Bretisilocin

EN Texto en inglés Aún no hay artículo en tu idioma: extracto en inglés.

Bretisilocin, also known by its developmental code name GM-2505 and as 5-fluoro-N-methyl-N-ethyltryptamine (5F-MET or 5-fluoro-MET), is a serotonergic psychedelic of the tryptamine family which is under development for the treatment of major depressive disorder. It is an analogue of dimethyltryptamine (DMT) and is the 5-fluorinated derivative of methylethyltryptamine (MET). Bretisilocin's route of administration is intravenous infusion. The drug acts as a potent and well-balanced serotonin 5-HT2A and 5-HT2C receptor agonist, serotonin 5-HT2B receptor partial agonist or antagonist, and serotonin releasing agent. It produces psychedelic-like effects in animals and similarly produces robust hallucinogenic effects in humans. The duration of bretisilocin is 60 to 90 minutes and is intermediate between the durations of DMT and psilocybin. It has been regarded by its developer as an "improved version of DMT". Bretisilocin was invented by Andrew Kruegel at Gilgamesh Pharmaceuticals and was patented in 2021. It is under development by Gilgamesh Pharmaceuticals. As of June 2025, the drug is in phase 2 clinical trials for the treatment of major depressive disorder. Bretisilocin was acquired from Gilgamesh Pharmaceuticals by AbbVie in a deal worth up to $1.2 billion in August 2025. It was encountered as a novel recreational designer drug in 2026.